Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cullin-3-RING ligase complex with Kelch repeat and BTB domain-containing protein 4 substrate receptor (CRL3^KBTBD4) is a multi-subunit E3 ubiquitin ligase that plays a critical role in protein homeostasis and epigenetic regulation (1.1.1, 1.2.1). KBTBD4 serves as the substrate-specific adapter, utilizing its BTB domain to bind the Cullin-3 scaffold and its Kelch domain to recruit targets for ubiquitination (1.2.1, 1.3.2). In its wild-type state, the complex regulates specific cellular substrates, but recurrent in-frame insertion/deletion (indel) mutations in the KBTBD4 Kelch domain act as primary drivers in Group 3 and Group 4 medulloblastoma (1.1.2, 1.2.2). These mutations confer a neomorphic gain-of-function, enabling the ligase to recruit and degrade the CoREST transcriptional repressor complex, which includes LSD1 and HDAC1/2 (1.2.3, 1.2.5). This aberrant degradation leads to epigenetic rewiring, increased histone H3K4 methylation, and the activation of stemness-related genes that promote tumor progression (1.2.1, 1.3.2). Interestingly, the small molecule UM171 acts as a molecular glue that mimics these oncogenic mutations by inducing the same neomorphic interaction between wild-type KBTBD4 and the CoREST complex (1.2.4, 1.2.5). Conversely, HDAC inhibitors have been shown to disrupt the interaction between mutant KBTBD4 and its neo-substrates, suggesting a potential therapeutic vulnerability for KBTBD4-driven cancers (1.3.1, 1.3.3).
Neomorphic recruitment and degradation of the CoREST complex (LSD1-HDAC1/2-CoREST) via molecular glue interaction or oncogenic mutation.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cullin-3-RING ligase complex with Kelch repeat and BTB domain-containing protein 4 substrate receptor (CRL3^KBTBD4).